CALGB (Cancer and Leukemia Group B) is an acronym that refers to a former cooperative clinical research group focused on studying and investigating cancer and leukemia. Initially formed in 1955, CALGB represented a collaborative effort between cancer researchers and physicians across multiple institutions within the United States. Its main objective was to conduct clinical trials and research studies aimed at advancing our understanding of different types of cancers, their prevention, treatment, and management.
CALGB played a crucial role in the field of oncology as it served as a platform for researchers to conduct clinical trials, share findings, exchange information, and collaborate on initiatives related to cancer treatment. The group comprised a network of oncologists, pathologists, physician-scientists, and other healthcare professionals who contributed their expertise and resources to the implementation of innovative clinical trials that have significantly influenced the practice of cancer medicine.
In 2012, CALGB merged with two other cooperative groups, the American College of Surgeons Oncology Group (ACOSOG) and the North Central Cancer Treatment Group (NCCTG), to form a single entity known as the Alliance for Clinical Trials in Oncology. This merger aimed to consolidate resources, enhance collaboration, and increase the efficiency of conducting cancer research and clinical trials on a larger scale.
Overall, CALGB represented a pioneering cooperative research group that fostered advancements in cancer treatment and patient care through its multi-institutional collaborations, clinical trials, and research studies.
